Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria

被引:29
|
作者
Landau, Michael A. [1 ]
Zhu, Benjamin [1 ]
Akwuole, Frances N. [1 ]
Pai, Reetesh K. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
关键词
colon cancer; tumor deposit; tumor budding; survival; stage IIl; KRAS; BRAF; MSI; mismatch repair; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; VENOUS INVASION; LYMPH-NODES; TNM; IMPACT; ADENOCARCINOMA; CARCINOMA; KRAS;
D O I
10.1177/1066896918787275
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Patients with stage III colonic adenocarcinoma have a spectrum of risk for recurrent disease, and histopathological variables that predict recurrence can help stratify patients into prognostic groups. To identify histopathological predictors of recurrence, we investigated the effect of implementation of the eighth edition of the American Joint Committee on Cancer (AJCC8) staging system definition of tumor deposits and International Tumor Budding Consensus Conference (ITBCC) criteria for tumor budding compared with other known prognostic variables in 256 resected colonic adenocarcinomas, including 150 stage III and 106 stage II tumors. In stage III colon cancer, tumor deposits and high tumor budding were the only independent histological variables that predicted disease recurrence. In a multivariable analysis in stage III colon cancer, tumor deposits and high tumor budding were associated with a 2.2- and 1.5-fold increased risk of developing disease recurrence, respectively (95% CI = 1.1-4,2, P = .02, and 95% CI = 1.1-2.1, P = .01, respectively). The negative prognostic effect of tumor deposits was most pronounced in patients with stage IIIB disease in which tumor deposits were associated with a 3.2-fold increased risk of disease recurrence (95% CI = 1.4-7.1; P = .005). Within the N1 cohort, patients with tumor deposits without concurrent positive lymph nodes (N1c) had a significantly decreased disease-free survival compared with patients with N0 tumors (P < .001) and patients with N1a/b tumors (P = .02). As independent risk factors for recurrence, tumor deposits and high tumor budding are important histopathological variables and should be included as a part of a routine comprehensive pathological risk assessment in stage III colon cancer.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 50 条
  • [11] Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
    Lurje, Georg
    Zhang, Wu
    Yang, Dongyun
    Groshen, Susan
    Hendifar, Andrew E.
    Husain, Hatim
    Nagashima, Fumio
    Chang, Heung M.
    Fazzone, William
    Ladner, Robert D.
    Pohl, Alexandra
    Ning, Yan
    Iqbal, Syma
    El-Khoueiry, Anthony
    Lenz, Heinz-Josef
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (02): : 161 - 168
  • [12] Prognostic Significance of Tumor Deposits in Patients With Stage III Colon Cancer: A Nomogram Study
    Zheng, Peilin
    Chen, Qiaoxing
    Li, Jiake
    Jin, Canguang
    Kang, Lina
    Chen, Donghan
    JOURNAL OF SURGICAL RESEARCH, 2020, 245 : 475 - 482
  • [13] Lymphovascular invasion, perineural invasion, and tumor budding are prognostic factors for stage I colon cancer recurrence
    Kim, Seijong
    Huh, JungWook
    Lee, Woo Yong
    Yun, Seong Hyeon
    Kim, Hee Cheol
    Cho, Yong Beom
    Park, Yoon Ah
    Shin, Jung Kyong
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (05) : 881 - 885
  • [14] Lymphovascular invasion, perineural invasion, and tumor budding are prognostic factors for stage I colon cancer recurrence
    Seijong Kim
    Jung Wook Huh
    Woo Yong Lee
    Seong Hyeon Yun
    Hee Cheol Kim
    Yong Beom Cho
    Yoon Ah Park
    Jung Kyong Shin
    International Journal of Colorectal Disease, 2020, 35 : 881 - 885
  • [15] Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer
    Betge, Johannes
    Kornprat, Peter
    Pollheimer, Marion J.
    Lindtner, Richard A.
    Schlemmer, Andrea
    Rehak, Peter
    Vieth, Michael
    Langner, Cord
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (12) : 3706 - 3712
  • [16] Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer
    Johannes Betge
    Peter Kornprat
    Marion J. Pollheimer
    Richard A. Lindtner
    Andrea Schlemmer
    Peter Rehak
    Michael Vieth
    Cord Langner
    Annals of Surgical Oncology, 2012, 19 : 3706 - 3712
  • [17] Prognostic value of tumor budding in patients with stage II and III colon cancer: A singleinstitution experience.
    Vinal, David
    Rueda-Lara, Antonio
    Martinez-Perez, Daniel
    Zwisler, Patricia
    Garcia-Leal, Andrea
    Ruiz-Gutierrez, Iciar
    Jimenez-Bou, Diego
    Pena-Lopez, Jesus
    Alameda-Guijarro, Maria
    Martin-Montalvo, Gema
    Perez-Wert, Pablo
    Martinez-Recio, Sergio
    Elena Palacios, Maria
    Ghanem, Ismael
    Custodio, Ana B.
    Gutierrez-Sainz, Laura
    Feliu, Jaime
    Rodriguez Salas, Nuria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 247 - 247
  • [18] Correction to: Lymphovascular invasion, perineural invasion, and tumor budding are prognostic factors for stage I colon cancer recurrence
    Seijong Kim
    Jung Wook Huh
    Woo Yong Lee
    Seong Hyeon Yun
    Hee Cheol Kim
    Yong Beom Cho
    Yoon Ah Park
    Jung Kyong Shin
    International Journal of Colorectal Disease, 2020, 35 : 1171 - 1171
  • [19] Combined analysis of tumor budding and tumor microenvironment in patients with stage III colorectal cancer.
    Nakajima, Hiromichi
    Inoshita, Naoko
    Kondoh, Chihiro
    Ozaki, Yukinori
    Tomizawa, Kenji
    Hanaoka, Yutaka
    Toda, Shigeo
    Tanabe, Yuko
    Miura, Yuji
    Moriyama, Jin
    Matoba, Shuichiro
    Kuroyanagi, Hiroya
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [20] Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer
    P Bohanes
    D Yang
    F Loupakis
    M J LaBonte
    A Gerger
    Y Ning
    C Lenz
    F Lenz
    T Wakatsuki
    W Zhang
    L Benhaim
    A El-Khoueiry
    R El-Khoueiry
    H-J Lenz
    The Pharmacogenomics Journal, 2015, 15 : 226 - 234